Recent advances in therapy for patients with chronic hepatitis B (CHB) infection offer the potential for a more successful treatment outcome, but also raise a number of questions in clinical practice regarding diagnosis and staging of CHB to ensure such potential is realized. In patients without cirrhosis, some forms of antiviral therapy can switch patients from an active disease phase into an inactive hepatitis B surface antigen (HBsAg) carrier state, and eventually lead to HBsAg clearance and HBsAg antibody seroconversion, the closest to a cure in CHB; thus, one of the most important diagnostic questions that clinicians face is the identification of patients with early forms of CHB within a large cohort of asymptomatic HBsAg-positive individuals, most of whom are inactive HBsAg carriers. Two major categories of diagnostic markers are currently available: virus-specific markers and liver disease markers. Most markers involve the use of non-invasive serological testing, but invasive diagnostic procedures, such as liver biopsy, are also an option. In this article, we review current opinions on the appropriate use of diagnostic procedures, answering some important questions for the clinician, such as why, how, when and in whom they might best be used.
Recent advances in therapy for patients with chronic hepatitis B (CHB) infection offer the potential for a more successful treatment outcome, but also raise a number of questions in clinical practice regarding diagnosis and staging of CHB to ensure such potential is realized. In patients without cirrhosis, some forms of antiviral therapy can switch patients from an active disease phase into an inactive hepatitis B surface antigen (HBsAg) carrier state, and eventually lead to HBsAg clearance and HBsAg antibody seroconversion, the closest to a cure in CHB; thus, one of the most important diagnostic questions that clinicians face is the identification of patients with early forms of CHB within a large cohort of asymptomatic HBsAg-positive individuals, most of whom are inactive HBsAg carriers. Two major categories of diagnostic markers are currently available: virus-specific markers and liver disease markers. Most markers involve the use of non-invasive serological testing, but invasive diagnostic procedures, such as liver biopsy, are also an option. In this article, we review current opinions on the appropriate use of diagnostic procedures, answering some important questions for the clinician, such as why, how, when and in whom they might best be used.
Since HBV was originally discovered in 1965 by detection of its surface antigen (HBsAg) in the serum of HBV-infected individuals [1] , many other antigenic and nucleic acid components of the virus have been identified and characterized [2] [3] [4] [5] [6] [7] [8] . In line with the progressive unravelling of HBV molecular biology, a series of diagnostic assays were set up for the detection of HBV markers in biological materials [8] [9] [10] [11] [12] . Detection of viral antigens and nucleic acids in clinical specimens contributed to a better understanding of the pathobiology of HBV infection and, at the same time, provided new potential tools for the clinical management of HBV infection and disease [9] [10] [11] [12] [13] [14] [15] [16] . The applications of both immunometric and molecular biology assays in clinical practice allowed the characterization of the four different phases of HBV infection and the two major forms of chronic hepatitis B (CHB), namely hepatitis B e antigen (HBeAg)-positive CHB and HBeAg-negative/ HBeAg antibody (anti-HBe)-positive CHB [10, 11, 16] . The number of commercially available tests to detect HBV markers has progressively increased in parallel with progressive improvements in terms of sensitivity and quantification potential. In addition, new diagnostic tools have been introduced to assess liver disease and new, more sensitive, techniques have been proposed to detect intrahepatic HBV, even in the absence of serological markers of HBV infection. This poses a series of new questions related to the most appropriate use of this battery of available tests in different clinical settings.
Current knowledge of HBV molecular biology and pathobiology, the natural history of HBV infection and disease, and the treatment options for CHB are reviewed in separate manuscripts in this supplement. We present here a systematic review of the clinical significance of HBV markers and their relevance to the most important questions in the management of HBV infection and disease in order to provide the clinician with an understanding of new data concerning the rationale, basis and clinical meaning of markers of HBV infection and liver disease. 
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Diagnostic markers of chronic hepatitis B infection and disease
Ferruccio
Introduction
Viral markers
The current diagnostic repertoire of HBV serum markers includes viral antigens and antibodies detected or measured by immunoassays and viral DNA measured by PCR-based amplification assays. In addition, we might detect both viral antigens (HBsAg and hepatitis B core antigen [HBcAg] ) and viral nucleic acids in liver tissue by immunohistochemistry and PCR, or by using in situ hybridization. When selecting the most appropriate assay, it is important to note that their diagnostic relevance is related to the biological properties of the particular markers they detect. Table 1 summarizes the clinical significance of the qualitative detection of various HBV markers. HBsAg forms part of the envelope of the virion that contains the viral nucleocapsid and nucleic acid, but also exists in large quantities within the serum, in the form of defective particles (nucleocapsid-and nucleicacid-free) that circulate in the blood, which outnumber the virion approximately 10 2 -10 5 times [2, 3] . Individuals with HBsAg in their serum have overt HBV infection, but do not necessarily have active liver disease, and the great majority of inactive HBV carriers have normal livers [4] [5] [6] . In general, the disappearance of serum HBsAg and antibody against HBsAg (anti-HBs) seroconversion follow recovery, and represents the closest to a cure in both acute and chronic infection. Following anti-HBs seroconversion, occult HBV infection (defined as the presence of HBV DNA in the liver with detectable [<200 IU/ml] or undetectable HBV DNA in serum of individuals who are HBsAg-negative) persists throughout the lifespan as documented by the indefinite persistence of serum antibody against hepatitis B core antigen (anti-HBc) [7] ; thus, anti-HBc can be considered the marker of overall exposure to HBV infection. In the absence of HBsAg, serum anti-HBs indicates protective immunity against HBV acquired by vaccination (anti-HBc-negative) or natural infection (anti-HBc-positive) [8] .
HBeAg, the secretory form of HBcAg, is released into the serum, whereas structural HBcAg is assembled within the nucleocapsid of the virion and is therefore covered by the virion envelope [8] . Detection of HBeAg in serum is the hallmark of the first phase of infection with wild-type HBV. In HBeAg-positive carriers who tolerate HBV and have high levels of HBV replication, liver damage is usually absent or minimal; thus, HBeAg is a marker of replicative HBV infection, but does not provide any diagnostic indication of liver disease. However, its association with markers of liver disease is a strong diagnostic indication for HBeAg-positive CHB. HBeAg clearance and anti-HBe seroconversion indicates the switch from HBeAg-positive CHB to the inactive HBV carrier state; however, HBeAg can disappear from the serum because of the selection of HBeAg-defective viruses, which results in persistent active HBeAg-negative CHB in HBsAg carriers [5, [9] [10] [11] .
HBV DNA represents the direct product and hallmark of viral replication; however, levels of serum HBV DNA in patients with CHB do not correlate directly with the degree of HBV-induced liver disease. Indeed, the highest HBV DNA serum levels are usually found in HBeAgpositive individuals with normal liver and characterize the immune tolerant phase of chronic infection. By contrast, the lowest HBV DNA levels are persistently found in inactive HBeAg-negative, anti-HBe-positive HBsAg carriers where viral replication is kept under effective immune control. Intermediate levels of serum HBV DNA are usually found in CHB patients, fluctuating at higher levels in HBeAg-positive CHB and at lower levels in HBeAg-negative CHB; thus, detection of intermediate HBV DNA levels in both HBeAg-positive and HBeAgnegative HBsAg carriers is strongly indicative of CHB.
Clinical significance of quantification of HBV markers
HBV DNA
The availability of highly standardized quantitative real-time PCR assays for HBV DNA detection has allowed improved investigation of the relationship between viral replication and the natural history of HBV. The REVEAL study, which included predominantly HBeAg-negative patients, showed that liver disease progression was intrinsically linked to the extent of viral replication [12] , although this might not be the case for patients in all stages of the disease, including the immune tolerant phase [13] . Quantification of serum HBV DNA has become a pivotal tool to guide the management of the HBV carriers, to identify different risks in terms of disease progression, to select candidates for antiviral therapy and to guide treatment with nucleoside/nucleotide analogues (NAs), which Serum HBV DNA is a direct marker of HBV infection, a direct marker of HBV replication and an indirect marker of HBV-induced liver disease if >20,000 IU/ml in an antibody against hepatitis B e antigen (HBeAg; anti-HBe)-positive carrier. Serum HBV cannot be a marker of HBV-induced liver damage in HBeAg-positive carriers or be used to exclude the presence of HBV-induced liver disease if <2,000 IU/ml in non-repeated samples in HBeAg-negative, anti-HBe-positive carriers. Anti-HBc, antibody against hepatitis B core antigen; anti-HBs, antibody against hepatitis B surface antigen; HBsAg, hepatitis B surface antigen; IgM, immunoglobulin M.
have potent direct antiviral activity [14] . Monitoring criteria during therapy are covered in other articles in this supplement. Serum HBV DNA describes the viral status at the time of detection, but it is not representative of the overall equilibrium between host immunity and virus replication. Indeed, HBV DNA might fluctuate widely and become temporarily undetectable in HBeAg-negative CHB, or reactivate as soon as NAs are discontinued in patients who responded to antiviral treatment and in whom HBV DNA was undetectable. We could speculate whether this is just a matter of sensitivity of the assays used to detect viraemia, but even if we had assays that were more sensitive by 4-5 log 10 , we would still need to repeat serum testing because of fluctuations in HBV DNA, which are particularly wide in carriers with low viral loads. Thus, the need for complementary assays has prompted recent interest in the quantification of serum HBeAg and HBsAg.
HBeAg
HBeAg is a surrogate marker of HBV replication with high HBV DNA levels and high infectivity. Approximately 90% of HBeAg-positive mothers transmit HBV to their babies compared with 10-20% of HBeAgnegative mothers [15] . Presence of HBeAg for >10 weeks in patients with acute hepatitis B infection indicates a high chance of transition to chronic infection [16] . Persistence of HBeAg seropositivity has been shown to be associated with disease progression and to be a significant risk factor for the development of cirrhosis and hepatocellular carcinoma (HCC) [17] [18] [19] [20] . Persistence of HBeAg positivity in patients over the age of 40 years is associated with a higher incidence of cirrhosis and poorer prognosis [21] [22] [23] [24] [25] [26] . Spontaneous HBeAg seroconversion is associated with low HBV DNA levels and clinical remission of liver disease in the majority of the patients [18, 21, 25, 27] . Earlier HBeAg seroconversion is associated with a higher rate of sustained remission and slower progression of liver disease [22, 25, 28, 29] . Treatment-induced HBeAg seroconversion has been shown to be associated with improvement in liver disease, and better overall and liver complication-free survival [30] . In addition, HBsAg clearance is more commonly seen in patients with treatment-induced HBeAg seroconversion than those without HBeAg seroconversion. HBsAg clearance rate increases over time following sustained HBeAg seroconversion; therefore, HBeAg seroconversion is an important therapeutic milestone in HBeAg-positive patients and is one of the important therapeutic goals. In a recent study, patients with lower HBeAg levels at weeks 12 and 24 of pegylated interferon-α2a treatment had higher HBeAg seroconversion rates (52% in patients with HBeAg<10 Paul Ehrlich Institute units [PEIU]/ml and 4% in patients with HBeAg>100 PEIU/ml at week 24) [31] . Quantitative HBeAg measurement during pegylated interferon therapy might, therefore, represent a useful measurement for predicting therapeutic response.
HBsAg
Quantification of HBsAg was introduced >20 years ago and has been significantly improved recently by the introduction of new automated assays [32] . The correlation between HBsAg levels and HBV DNA kinetics is complex and varies in different disease states. Early studies showed that subviral HBsAg particles (22 nm spherical filaments) exceed virions by a variable factor of 10 2 -10 5 and can accumulate in concentrations up to several hundred µg per ml of serum [2, 3] . In highly viraemic HBeAg-positive CHB, subviral HBsAg particles are in larger excess, whereas the opposite occurs in low viraemic anti-HBe-positive CHB. In both Asian and European patients with CHB, Nguyen et al. [3] and Jaroszewicz et al. [33] showed that median HBsAg levels differ significantly during the four phases of HBV infection, decreasing progressively from the immune tolerant (4.5-4.96 log 10 IU/ml) to the inactive HBV carrier state (2.86-3.09 log 10 IU/ml). These findings indicate that HBsAg secretion varies in the course of CHB infection, and that HBsAg and HBV DNA serum levels are weakly correlated. In clinical practice, the differential diagnosis between active CHB and the inactive HBV carrier state is difficult because HBeAg-negative CHB is characterized by wide fluctuations in viral replication and biochemical activity, with decreases in HBV DNA serum levels below the inactive carrier cutoff and spontaneous normalization of alanine aminotransferase (ALT) levels lasting from a few weeks to several months [34, 35] . In a large prospective cohort study of untreated HBeAg-negative/anti-HBe-positive genotype-D-infected asymptomatic carriers who were strictly monitored monthly for at least 1 year, Brunetto et al. [36] showed that combined single-point quantification of HBV DNA and HBsAg provided the most accurate diagnosis of the phase of HBV infection in asymptomatic HBeAg-negative, HBsAg-positive patients. In this study, HBsAg serum levels <1,000 IU/ ml and HBV DNA≤2,000 IU/ml identified the inactive HBV carrier state with 94.3% diagnostic accuracy, 91.1% sensitivity and 95.4% specificity, with a positive predictive value (PPV) of 87.9% and negative predictive value (NPV) of 96.7%. Similar prospective studies with stringent monitoring criteria are needed to address the correlations between other HBV genotypes and the dynamics of HBsAg serum levels during the different phases of HBV infection. Preliminary data have also demonstrated a potential role for quantitative serum HBsAg in on-treatment prediction of virological response to CHB therapy; this issue is discussed in detail in other articles in this supplement.
Antibody levels
Serum anti-HBc is the most useful and inexpensive diagnostic marker for the identification of occult HBV infection in HBsAg-negative individuals [7] . High titres of anti-HBc (>1/100 dilution) indicate indirectly the persistence of HBV DNA in the nuclei of hepatocytes as integrated or supercoiled forms [8] ; thus, detection of anti-HBc is a very useful screening tool in patients undergoing immune suppressive and antiblastic therapies, and in identifying candidates for prophylactic treatment with NAs to prevent severe and life-threatening HBV reactivation [37] . Quantification of anti-HBs provides a useful means of monitoring post-liver-transplant therapy with human anti-HBs immune γ-globulin in HBV-positive patients and to ascertain response to HBV vaccines.
HBV genotypes
Eight genotypes of HBV (designated A-H) have been identified by sequence divergence of >8% over the entire genome of HBV DNA [38] [39] [40] . Epidemiological studies have shown that each genotype has a characteristic geographic and ethnic distribution (Table 2 ) [41] [42] [43] [44] [45] . Genotype A is widely distributed in Northwest Europe, North America and Central Africa, whereas genotypes B and C are prevalent in Asia. Genotype D is commonly found in the Mediterranean area, the Middle East and India. Genotype E is restricted to sub-Saharan Africa and genotype F is found in South and Central America. Genotype G has been found in France, Germany, the United States, Central America and Mexico. The recently discovered genotype H appears so far to be restricted to Latin America. Unlike hepatitis C genotypes, HBV genotypes have a limited application to the study of the natural history and treatment of CHB. In addition, because of the unique distribution of HBV genotypes in Asian and Western countries, the clinical significance of HBV genotype can be reliably compared only between genotypes B and C or genotypes A and D.
The relationship between HBV genotypes and the tendency of chronic infection has been elucidated. Suzuki et al. [46] reported that higher persistence of HBV infection is seen in genotype-A-infected individuals (23% in genotype A versus 11% and 7% in genotypes B and C, respectively). The rate of chronicity of acute genotype D infection is higher than that of genotype B and C infection [47] [48] [49] . In patients with CHB, genotype B is associated with spontaneous HBeAg seroconversion at a younger age [50] . The estimated rates of spontaneous HBeAg seroconversion are 15.5% and 7.9% per year in genotypes B and C, respectively [51] . The mean ±sd age at HBeAg seroconversion of genotype C is one decade older than that of genotype B (41 ±10 versus 30 ±8 years), suggesting a longer duration of high HBV replication and disease activity in genotype C infection [51] [52] [53] [54] [55] ; therefore, genotype C is more likely to be associated with persistent HBeAg-positive CHB despite multiple episodes of hepatitis flares, and is associated with more aggressive and progressive liver disease [56] . By contrast, genotype B infection has a slower progression of liver fibrosis and less active liver disease than genotype C infection [57] . HBV genotype C is associated with an increased risk of cirrhosis and HCC compared with genotype B [58] [59] [60] [61] [62] . In addition, the risk of HCC increases with increasing HBV viral load. Liu and Kao [63] found that genotype C has a higher frequency of the basic core promoter T1762/ A1764 mutation than genotype B (50% versus 6%). Men who had HBV genotype C infection with a very high viral load had a 26-fold higher risk of HCC than those with other genotypes and low or undetectable viral load [64] . HBV genotype B might be associated with a faster transition through the immunoreactive stage and evolution into the residual phase; however, genotype B has been reported to be associated with HCC in young non-cirrhotic patients with CHB infection [59, 65] . A prospective study of 258 Spanish patients with CHB infection has shown significantly lower baseline HBeAg positivity in patients with genotype D than those with genotype A (36% versus 80%; P<0.0001) [65] . The rate of sustained remission after HBeAg seroconversion was higher in genotype A than genotype D (55% versus 32%; P<0.01) [65] . Genotype D might be associated with more active CHB with a higher frequency of increased serum ALT levels [66] . A study from India suggested that genotype D is associated with more severe liver disease and might be associated with HCC in young patients [67] . Regarding HBsAg clearance, genotype B has higher spontaneous HBsAg clearance rate than genotype C [68] . Genotype A also has a higher rate of HBsAg clearance than genotype D (16% versus 8%; P=0.03) [65] . The influence of HBV genotype on response to HBV treatment is only partially understood. Because of the unique distribution of HBV genotypes in different geographic areas, therapeutic implications of HBV genotype have mostly been compared between genotypes B and C or genotypes A and D. Patients infected with HBV genotype C have poorer sustained response to conventional interferon-α therapy than genotype B (generally 20% versus 40% in HBeAg-positive CHB) [69] [70] [71] [72] , and HBV genotype C is also associated with a lower rate of HBeAg and HBsAg seroconversion [73] [74] [75] [76, 77] . In our Phase II study, genotype-B-infected patients showed better rates of HBeAg seroconversion after a 24-week course of pegylated interferon-α2a compared with genotype-C-infected patients (33% versus 21%) [78] . Janssen et al. [79] reported that the rate of response to pegylated interferon-α2b therapy varied according to HBV genotypes (genotype A, 47%; B, 44%; C, 28%; and D, 35%). However, our large Phase III clinical trial including a greater number of patients infected with genotype B and genotype C showed no difference in HBeAg seroconversion rate 24 weeks post-treatment following a 48-week course of pegylated interferon-α2a in these genotypes (30% versus 31%) [80] . The association of HBV genotype with response to pegylated interferon therapy, particularly genotype B and genotype C infection, needs to be confirmed by further studies. HBV genotype A is associated with a higher HBsAg seroconversion rate following treatment with pegylated interferon than other genotypes in both HBeAg-positive and HBeAg-negative CHB [81, 82] . Studies from Asia showed no difference in biochemical or virological response to lamivudine therapy between genotype B and genotype C [83] [84] [85] . Buti et al. [86] also reported that the response to lamivudine therapy was similar between genotypes A and D. However, Chien et al. [87] reported that patients with genotype B infection had a higher sustained response rate to lamivudine than those with genotype C (61% versus 25%; P=0.009). The chances of YMDD mutations with virological and biochemical breakthrough are similar in patients with genotype B and genotype C infection [84] . Although the emergence of YMDD mutation was only slightly higher in patients with genotype A infection than in those with genotype D, the difference was seen only during the first year of lamivudine therapy and was no longer seen after extended treatment of 2 years or more [86] . HBV genotypes do not appear to have an effect on virological response, HBeAg seroconversion or on emergence of drug resistance during adefovir dipivoxil therapy [69, 88] . One recent study showed that virological response and histological improvement to entecavir therapy were similar among different HBV genotypes in both HBeAg-positive and HBeAg-negative patients [89] . Determining HBV genotype could be helpful to identify the patients who might be at greater risk of liver disease progression and as a predictor of outcome to HBV therapy; thus, HBV genotyping in patients with CHB infection provides further information for clinical and virological investigations in order to identify both high-risk patients and the most appropriate candidates for specific treatment. Nevertheless, most of the results have been obtained from regional studies with limited genotypes and the number of patients studied was relatively small. Further studies are essential before making appropriate recommendations.
Non-invasive liver disease markers
Serum markers
Although often considered to be sensitive and specific markers of liver disease, serum transaminase levels can be affected by a number of factors, including stage of infection. There are, therefore, limitations to its use as an independent diagnostic marker. Increases in serum transaminases in association with intermediate or high levels of serum HBV DNA are highly indicative of CHB, although the 'gold standard' for aetiological diagnosis of CHB would require detection of intrahepatic chronic necroinflammatory lesions associated with immunohistochemical staining for HBcAg in the nuclei of HBV-infected hepatocytes.
The combination of serum markers has been shown to predict liver fibrosis and activity in a number of studies [90, 91] . Aminotransferases and indices including α(2)-macroglobulin, apolipoprotein A1, haptoglobin, γ-glutamyl transpeptidase, total bilirubin (FibroTest ® ) and ALT (Actitest) have been shown to be accurate markers of HBV-related activity and fibrosis compared with liver biopsy [92, 93] , to accurately define prognosis and inactive HBV carrier status in combination with HBV viral load [94] , and to be an effective means of non-invasive monitoring during antiviral therapy [95] . Although such data needs to be confirmed and validated, combining serum markers has the potential, if not to fully replace the liver biopsy, to at least reduce the need for biopsy in a substantial proportion of patients.
Liver stiffness
Transient elastometry as measured by FibroScan ® was recently proposed as a rapid, easy to perform, reproducible, non-invasive technique for the evaluation of liver stiffness. A large number of studies have investigated the ability of this new technique for the indirect assessment of hepatic fibrosis, comparing it with the 'gold standard' of liver biopsy. The technique appears very helpful for categorizing patients into three major groups: patients without fibrosis, patients with significant fibrosis and patients with cirrhosis. These results and the easy application of this technique has led to a rapidly growing interest in its use in clinical practice. This issue is discussed in detail in this supplement.
Discrepancies between virus and liver disease markers
There are essentially two major clinical conditions where there is a need to exclude other possible cofactors of liver disease: firstly, in HBeAgpositive carriers with high HBV DNA serum levels and secondly, in HBeAg-negative, anti-HBepositive carriers with very low levels of HBV DNA (<2,000 IU/ml). In both conditions, liver damage might be unrelated to HBV, but instead could be caused by other disease cofactors. The exclusion of such cofactors involves testing for serum markers of other viral infections, autoantibodies and non-viral causes of liver disease. Very important information could be provided by the simple non-invasive detection of immunoglobulin (Ig)M anti-HBc antibodies in the serum. Since 1986, a well-defined standardized cutoff of IgM anti-HBc serum levels has been agreed, and low levels of this antibody detected by means of sensitive (up to 1-5 PEIU/ml) [96] assays have been shown to be associated with CHB with very high sensitivity and specificity [97, 98] ; thus, anti-HBc IgM antibody is the most specific marker of HBV-induced liver disease in both acute and CHB (Table 1) . However, a major limitation is the lack of large standardized studies to answer the question of whether the measurement of IgM antiHBc serum levels is equally reliable when the test is performed using fresh or unfrozen serum [99] . In any controversial cases, a liver biopsy is indicated.
Liver biopsy
The liver biopsy is an invasive procedure, which is indicated only when a specific diagnosis of CHB cannot be posed or excluded using non-invasive procedures. The risk and benefits of the procedure have to be assessed appropriately in the individual patient, who should participate in the decision making process. For reliable histopathology analysis, liver specimens have to be at least 20 mm long and 1.4 mm wide. Qualitative and quantitative analysis of liver histology in chronic viral hepatitis are reviewed extensively elsewhere [100] .
Immunohistochemistry
Intrahepatic demonstration of viral antigens provides a very detailed diagnostic examination of the aetiology of CHB, and should be undertaken whenever there are doubts about the aetiology of liver disease in an HBsAg carrier. For instance, in highly viraemic HBeAgpositive carriers with liver disease, it is very important to determine the immunohistochemical pattern of HBcAg/HBsAg in the liver. Scattered nuclear positivity for HBcAg in up to two-thirds of the hepatocytes with sparse cytoplasmic positivity for both HBcAg and HBsAg is an immunohistochemical marker of CHB. Although the expression of nuclear HBcAg decreases and cytoplasmic HBcAg increases during the immune reactive phase, cytoplasmic HBcAg might diffuse and disperse shortly before HBeAg seroconversion [101] . By contrast, a diffuse HBcAg nuclear pattern (100% of hepatocytes) associated with HBsAg liver membrane staining is the hallmark of the immune tolerant phase. A proper stoichiometry between the L and S proteins of HBsAg is required for the secretion of both virions and defective filament particles [102, 103] . When expressed alone, the L protein is not secreted and accumulates in the pre-Golgi compartment, and its overexpression causes S protein accumulation in the Golgi complex and inhibits secretion of HBsAg particles. The progressive decrease of serum HBsAg levels during the natural history of HBV infection parallels the progressive increase of intrahepatic staining for HBsAg within the cell cytoplasm (not submembranous as in the immune tolerant phase), with typical features suggestive of accumulation of the protein (termed the 'ground glass cells' [GGC]). A role for pre-S HBV variants, selected by pressure from the host's immune response during the immune reactive phase, was advocated as a possible explanation of the asymmetry between HBsAg in the serum and intrahepatic levels [102, 103] . Indeed, some interesting reports [102] showed that it was possible to identify different types of GGC in the liver according to the type of pre-S mutants (pre-S1 or pre-S2): type I, occurring throughout the highly replicative (HBeAg-positive) phases, was shown to be scattered sporadically within the lobules and was associated with pre-S1 mutants; and type II, which was more frequently observed in the low replicative stage (HBeAg-negative), was distributed in large clusters with marginal expression of HBsAg.
Intrahepatic nucleic acids
In situ hybridization techniques were developed to detect intracellular nucleic acids while preserving liver morphology, but they did not prove to provide diagnostic advantages over immunohistochemistry [104] . Detection of covalently closed circular (ccc) HBV DNA and overall intrahepatic HBV DNA is a useful procedure for the study of variations between serum and intrahepatic viral loads during antiviral therapy (see other contributions in this supplement) [105] . HBV infection cannot be eradicated and persistence of HBV genomes in HBsAg-negative individuals is termed occult HBV infection. Occult HBV infection has a worldwide distribution, although available data of prevalence in various categories of individuals (with or without liver disease) varies because of different sensitivity and specificity in methodology and sampling errors of liver biopsies [106] . The presence of serum anti-HBc in HBsAg-negative individuals can be used as a surrogate marker of intrahepatic HBV DNA; however, the clinical implications of detecting occult HBV infection remain to be defined.
Conclusions
We have a wide array of markers of HBV infection and we need to rationalize their use in diagnostic packages tailored to provide the most appropriate answers to the different questions raised during HBV diagnosis in clinical practice. These questions might vary in different areas of the world, and prospective studies must address the performances of diagnostic algorithms using different combinations of HBV markers.
Quantification of serum HBV DNA is the most useful tool to monitor viral load as the result of viral replication, and can be used to address many of the issues around decisions regarding therapy.
Serum HBsAg levels are dependent on the complex equilibrium between HBV and the host's immune system. Levels largely reflect active transcription of the specific messenger RNA derived from ccc HBV DNA, and are only minimally linked with viral replication. We can not rule out the possibility that integrated HBV DNA might contribute to HBsAg synthesis, but the evidence that HBsAg serum levels decrease significantly with the duration of HBV infection, whereas the amount of integrated HBV DNA is supposed to increase, suggests only a minor contribution. The substantial variations in serum HBsAg between the different phases of HBV infection suggests that quantitative HBsAg might be a new diagnostic tool for the characterization of the HBV carrier in combination with HBV DNA. These two HBV markers provide complementary information on the status of HBV infection, which might be very useful in clinical practice to define the specific condition of the individual HBV carrier during the highly dynamic phases of chronic HBV infection -just as latitude and longitude allow us to define a ship's position in the ocean. This will be of particular importance in HBeAg-negative CHB, where the intermittent nature of the disease means a single-point serum test frequently shows normal transaminases and negative HBV DNA and so might lead to misclassification as an inactive HBV carrier; thus, the specificity and sensitivity of differential diagnosis between inactive HBV carrier status and HBeAgnegative CHB could be improved consistently by the use of a combination of ALT measurement, quantification of HBV DNA and HBsAg, and eventually adding liver elastometry and testing for low levels of IgM anti-HBc.
